GeneOnline Interview | Dr. Potria Lin

CDMO Opportunities Amid Global Supply Chain Restructuring

Highlights

• Global biopharma supply chain realignment creates new opportunities for biologics CDMOs.
• EirGenix leverages its dual-engine strategy combining CDMO services and biosimilar development.
• Taiwan is emerging as a trusted manufacturing partner in the global biologics ecosystem.

Read the full interview on GeneOnline. EirGenix Leverages Dual Engines of CDMO and Biosimilars to Capitalize on Global Biopharma Supply Chain Realignment - GeneOnline News